Aduro Biotech IPO priced at $17 per share, says underwriter-Reuters
Aduro Biotech Inc's initial public offering has been priced at $17 per share, an underwriter said, valuing the cancer immunotherapy drug developer at about $1 billion.
15 April 2015•1 min read
